Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125509871 | 12550987 | 1 | I | 20160704 | 20160713 | 20160713 | EXP | GR-ROCHE-1789126 | ROCHE | MATIKA A, KENTEPOZIDIS V, ARDAVANIS A, VASLAMATZIS M, POLYZOS A, EMMANOUILIDES C, KATSAOUNIS P, KOINIS F, XYNOGALOS S, CHRISTOPOULOU A, ZIRAS N, TEGOS T, PRINARAKIS E, HATZIDAKI D, GEORGOULIAS V AND KOTSAKIS A. EFFICACY AND TOLERANCE OF FRONTLINE BEVACIZUMAB-BASED CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS: A MULTICENTER, PHASE IV STUDY OF THE HELLENIC ONCOLOGY RESEARCH GROUP (HORG).. CANCER CHEMOTHERAPY AND PHARMACOLOGY 2016 JUN 22;:1-8. | 0.00 | Y | 0.00000 | 20160713 | OT | GR | GR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125509871 | 12550987 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | U | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | Q3W | ||||||
| 125509871 | 12550987 | 2 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | U | 0 | ||||||||||
| 125509871 | 12550987 | 3 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | U | 0 | ||||||||||
| 125509871 | 12550987 | 4 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | U | 0 | ||||||||||
| 125509871 | 12550987 | 5 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | U | 0 | ||||||||||
| 125509871 | 12550987 | 6 | SS | PEMETREXED | PEMETREXED | 1 | Unknown | U | 0 | ||||||||||
| 125509871 | 12550987 | 7 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 125509871 | 12550987 | 8 | SS | VINORELBINE | VINORELBINEVINORELBINE TARTRATE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125509871 | 12550987 | 1 | Non-small cell lung cancer |
| 125509871 | 12550987 | 2 | Non-small cell lung cancer |
| 125509871 | 12550987 | 3 | Non-small cell lung cancer |
| 125509871 | 12550987 | 4 | Non-small cell lung cancer |
| 125509871 | 12550987 | 5 | Non-small cell lung cancer |
| 125509871 | 12550987 | 6 | Non-small cell lung cancer |
| 125509871 | 12550987 | 7 | Non-small cell lung cancer |
| 125509871 | 12550987 | 8 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125509871 | 12550987 | OT |
| 125509871 | 12550987 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125509871 | 12550987 | Acute coronary syndrome | |
| 125509871 | 12550987 | Acute kidney injury | |
| 125509871 | 12550987 | Anaemia | |
| 125509871 | 12550987 | Deep vein thrombosis | |
| 125509871 | 12550987 | Diarrhoea | |
| 125509871 | 12550987 | Embolism | |
| 125509871 | 12550987 | Fatigue | |
| 125509871 | 12550987 | Febrile neutropenia | |
| 125509871 | 12550987 | Fungal infection | |
| 125509871 | 12550987 | Gastrointestinal perforation | |
| 125509871 | 12550987 | Haemorrhage | |
| 125509871 | 12550987 | Hypersensitivity | |
| 125509871 | 12550987 | Hypertension | |
| 125509871 | 12550987 | Leukopenia | |
| 125509871 | 12550987 | Neutropenia | |
| 125509871 | 12550987 | Pulmonary embolism | |
| 125509871 | 12550987 | Pulmonary haemorrhage | |
| 125509871 | 12550987 | Skin toxicity | |
| 125509871 | 12550987 | Sudden death | |
| 125509871 | 12550987 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |